Skip to content

Inspection Record

Berkshire Sterile Manufacturing — FDA 483 Findings

US FDAInspected 2024-10-21Published 2026-10-19 7 findingsOther quality systemAseptic processing and sterility assuranceDeviation, CAPA, and investigationEquipment and facilityContamination control

View the regulator's official source The source document is always the basis for judgement.

Findings

1Other quality system

Standard operating procedures and protocols are not followed, established, or adequate.

2Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

3Deviation, CAPA, and investigation

Written records of investigations into unexplained discrepancies do not always include appropriate documentation, conclusions, and follow-up.

4Equipment and facility

The facility is not adequately maintained.

5Aseptic processing and sterility assurance

Procedures designed to prevent microbial contamination of drug products purporting to be sterile are not established, written, or followed.

6Aseptic processing and sterility assurance

The program for the visual inspection (VJ) of sterile injectable drug products does not provide adequate assurance that finished products manufactured at the facility possess their purported quality attributes, including that they are free from particulate matter and critical defects.

7Contamination control

The!” formulation process is not adequately controlled or designed to minimize the contamination risk of upstream drug product manufacturing steps.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-19. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Berkshire Sterile Manufacturing findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.